argenx registers Phase 2 trial of empasiprubart for Guillain-Barré syndromeSep 16Trial updateargenxempasiprubart
argenx opens Phase 1 bioequivalence trial comparing efgartigimod autoinjector to prefilled syringeAug 24Trial updateargenxefgartigimod
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositisAug 17Clinical readoutargenxefgartigimod
argenx posts ADAPT SERON Phase 3 results; registers new Phase 2 in Sjögren's neuropathyAug 12Weekly roundup, 2 itemsargenxefgartigimod
argenx registers Phase 3 trial of adimanebart in rare congenital myasthenic syndromesAug 4Trial updateadimanebartargenx
argenx registers Phase 2a empasiprubart trial in gMG; adimanebart PK study recruitingJun 29Weekly roundup, 2 itemsadimanebartargenx
Sign in